Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Hospital-acquired infection wikipedia , lookup
Osteochondritis dissecans wikipedia , lookup
Common cold wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Signs and symptoms of Graves' disease wikipedia , lookup
Management of multiple sclerosis wikipedia , lookup
Gastroenteritis wikipedia , lookup
Rheumatoid arthritis wikipedia , lookup
Osteoporosis and Aging An estimated 25 million Americans have osteoporosis. It affects elderly people of all races and ethnicities. 20-25% of persons with a hip fracture are unable to return to independent living and 12-20% die within 1 year. Diagnostic Approach Screening Risk Factors 65+ Female Age Physical activity Gender Currently smoking Previous fracture Family history Rheumatoid arthritis Low BMI Alcohol use DXA for all Women 65+ years Fracture (Major Trauma NA) No Fracture DXA (Baseline) DXA and FRAX Diagnosis Osteoporosis Osteopenia Normal Steroid use >-1.0 DXA Treat T-Score ≤ -2.5 -1.0 to -2.4 > -1.0 False Positives with Compression Fractures No Treatment Treatment Drug Bisphosphonates (Reclast®, Fosamax®, Alendronate®, Boniva®, Actonel®) Teriparatide (Forteo®) Route IV/PO MOA Inhibits osteoclast-mediated bone resorption Oral drugs should be given on an empty stomach with a fullglass of water, patient should stay up-right for 30-min after ingestion Subq Self administered at home Stimulates new bone formation Not recommended for use longer than 2-years ADR Atrial fibrillation, rash, injection site reaction, abdominal pain, constipation, nausea, diarrhea, vomiting, indigestion, flatulence, backache, asthenia, headache,fatigue, fever, influenza-like symptoms, bronchitis, upper respiratory infection * Zoledronic acid (Reclast®) should be avoided in patients with CrCl <30 ml/min Hypotension, syncope,rash, sweating, hyperuricemia, constipation, nausea, diarrhea, vomiting, indigestion, arthralgia, spasm, asthenia, dizziness, increased frequency of cough, pharyngitis, rhinitis References: J Clin Epidemiol 50:683; Menopause 5:226; J New Zealand Med 119:1246; J Bone and Min Res, 2010. < -2.5 Treat -1.0 to - 2.4 DXA ≥ 3% FRAX (Hip Fracture) Treat ≥ 20% FRAX (Osteoporotic Related Fracture) Treat To view the online FRAX calculator, visit: http://www.shef.ac.uk/FRAX/t ool.jsp?country=9 FRAX should not be used with persons on treatment for Osteoporosis Aging Q3 is funded by the DW Reynolds Foundation